<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 12b-25
Commission File Number 0-26918
Notification of Late Filing
(Check one): |X| Form 10-KSB [ ] Form 11-K
[ ] Form 20-F [ ] Form 10-QSB [ ] Form N-SAR
For Period Ended: December 31, 1997
------------------
[ ] Transition Report on Form 10-KSB [ ] Transition Report on Form 10-QSB
[ ] Transition Report on Form 20-F [ ] Transition Report on Form N-SAR
[ ] Transition Report on Form 11-K
For the Transition Period Ended: _____________________________________
Read Attached Instruction Sheet Before Preparing Form. Please Print or
Type.
Nothing in this Form shall be construed to imply that the Commission
has verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the item(s) to which the notification relates: _______________________
_______________________________________________________________________________
PART I
REGISTRANT INFORMATION
Full name of registrant Cytoclonal Pharmaceutics Inc.
------------------------------
Former name if applicable
________________________________________________________________________________
Address of principal executive office (Street and Number)
9000 Harry Hines Boulevard, Suite 330
- --------------------------------------------------------------------------------
City, state and zip code Dallas, Texas 75235
-------------------
PART II
RULE 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate.)
(a) The reasons described in reasonable detail in Part III of this
Form could not be eliminated without unreasonable effort or
expense;
<PAGE>
(b) The subject annual report, semi-annual report, transition
report on Forms 10-K, 10-KSB, 20-F, 11-K or Form N-SAR, or
portion thereof will be filed on or before the 15th calendar
day following the prescribed due date; or the subject
[X] quarterly report or transition report on Form 10-Q, 10-QSB, or
portion thereof will be filed on or before the fifth calendar
day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Forms 10-K, 10-KSB,
11-K, 20-F, 10-Q, 10-QSB, N-SAR or the transition report portion thereof could
not be filed within the prescribed time period.
The registrant's independent auditors are currently conducting their
year-end audit and are unable to meet the Form 10-KSB March 31, 1998 filing
deadline. Once such auditors have completed their audit, the registrant will
file Form 10-KSB. See Exhibit A attached hereto.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification.
Robert H. Cohen, Esq. (212) 735-8680
--------------------- -------------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company
Act of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
|X| Yes [ ] No
(3) Is it anticipated that any significant change in results of
operations from the corresponding period for the last fiscal year will be
reflected by the earnings statements to be included in the subject report or
portion thereof?
| | Yes [X] No
If so: attach an explanation of the anticipated change, both
narratively and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
<PAGE>
Cytoclonal Pharmaceutics Inc.
- --------------------------------------------------------------------------------
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: March 31, 1998 By: /s/Arthur P. Bollon
--------------------- ---------------------------------------------
Arthur P. Bollon, Ph.D., Chairman and President
Instruction. The Form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the Form shall be typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative (other than an executive officer), evidence of the
representative's authority to sign on behalf of the registrant shall be filed
with the Form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal
criminal violations (see 18 U.S.C. 1001).
<PAGE>
Exhibit A
Richard A. Eisner & Company, LLP
[Letterhead]
March 30, 1998
Dr. Arthur Bollon
Cytoclonal Pharmaceutics, Inc.
9000 Harry Hines Boulevard
Dallas, Texas 75235
Dear Dr. Bollon:
Pursuant to your request, please be advised that pending receipt of the
requested cash flow projection information, we are unable to complete our audit
of the Company's financial statements as of and for the year ended December 31,
1997.
Very truly yours,
/s/Richard P. Shanley
-----------------------------------------
Richard P. Shanley, Partner
